Streetbeat News

Earnings

IINN

Inspira Technologies announced its FY23 cash and cash equivalents total at $7.361 million.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:25 pm

LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced four presentations on sotagliflozin at the American College of Cardiology session, highlighting its efficacy in reducing stroke and heart attack risk among patients with type 2 diabetes, CKD, and high CV risk. The FDA approved sotagliflozin in 2023 for reducing cardiovascular death and hospitalization in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:25 pm

LUCY

Innovative Eyewear (NASDAQ:LUCY) reported Q4 earnings with an EPS of $-0.19, missing estimates by -36.0%. Revenue increased by $548 thousand from the previous year. Last quarter, the company beat EPS estimates, which led to a 0.0% change in share price the following day.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 1:25 pm

IDR

Idaho Strategic Resources (AMEX:IDR) reported Q4 earnings with a -60.0% miss on estimated EPS, achieving $0.02 versus an estimate of $0.05. Revenue increased by $345 thousand year-over-year. The company's past performance shows variability in meeting EPS estimates, with a notable 4.0% share price drop following last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 1:20 pm

ARTL

Artelo Biosciences (NASDAQ:ARTL) reported Q4 earnings with an EPS of $-0.99, missing estimates by -77.0% and showing no revenue change from the previous year. Despite past earnings misses, the company's share price increased by 3.0% the day after the last earnings report.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 1:20 pm

BA

DBC

NVDA

PCG

On CNBC's 'Halftime Report Final Trades,' analysts recommended Boeing (BA), PG&E (PCG), Invesco DB Commodity Index Tracking Fund (DBC), and NVIDIA (NVDA). Boeing faces cash outflow concerns due to regulatory scrutiny. PG&E raised its FY24 earnings outlook after better-than-expected Q4 earnings. NVIDIA received a price target increase from UBS and unveiled new products at its GTC event. The stocks showed mixed performance on Friday, with BA and NVDA gaining, while PCG and DBC fell.

Portfolio Pulse from Avi Kapoor

March 25, 2024 | 1:17 pm

TFFP

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced its Phase 2 study of Tacrolimus Inhalation Powder for lung transplant rejection prevention will be presented at the ISHLT 2024 Meeting. The study suggests that this method could offer effective immunosuppression with lower systemic exposure than oral tacrolimus. The presentation will detail the trial's safety, tolerability, efficacy, and pharmacokinetics in patients with significant renal impairment.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:16 pm

OLK

Olink Holding (NASDAQ:OLK) reported Q4 earnings with an EPS of $-0.06, missing estimates by -140.0% compared to the expected $0.15. Revenue increased by $10.67 million from the same period last year. Despite past quarters showing mixed results, this quarter's earnings fell short of expectations.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 1:15 pm

AIM

AIM ImmunoTech announced the publication of a study in the Clinical Cancer Research journal, evaluating its drug Ampligen in the treatment of pancreatic cancer. The findings could have significant implications for the company's drug development pipeline and its position in the oncology market.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:10 pm

FRGT

Freight Technologies announced a preliminary Q4 revenue of $5M, marking a 7.5% increase from the previous quarter.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:06 pm